Today: 8 February 2026
Subscribe
Browse Category

NASDAQ:HRMY News 13 January 2026

Harmony Biosciences stock drops after ZYN002 exit as 2026 Wakix sales outlook tops $1 billion

Harmony Biosciences stock drops after ZYN002 exit as 2026 Wakix sales outlook tops $1 billion

Harmony Biosciences shares fell 6.4% to $35.82 Tuesday after the company cut its Fragile X program and issued 2026 sales guidance. Harmony forecast Wakix net revenue of $1.0–$1.04 billion for 2026 and confirmed it will phase out ZYN002. Preliminary Wakix revenue for 2025 was about $868 million. CEO Jeffrey Dayno is set to present at the J.P. Morgan Healthcare Conference later Tuesday.
13 January 2026
·

Stock Market Today

Thermo Fisher stock holds near $543 after Thursday slide as traders size up layoffs notice, data week ahead

Thermo Fisher stock holds near $543 after Thursday slide as traders size up layoffs notice, data week ahead

8 February 2026
cNew York, Feb 7, 2026, 17:29 EST — Market closed. Thermo Fisher Scientific (TMO.N) shares ended Friday, Feb. 6, at $542.83, steady on the day after a roughly 4% drop in the prior session. With U.S. markets shut on Saturday, traders head into Monday looking for signs the selloff has run its course. (Thermo Fisher Scientific) The stock has been jumpy because the company sits at the intersection of two messy lines: research spending that can disappear fast, and drugmakers’ demand for tools and services that tends to hold up. That split matters now because the next leg, up or
Disney stock ends week higher after Friday bounce — what to watch for DIS next week

Disney stock ends week higher after Friday bounce — what to watch for DIS next week

7 February 2026
Disney shares closed up 3.6% at $108.70 Friday, recovering from earlier losses as U.S. stocks rallied and the Dow topped 50,000. Investors are watching Super Bowl streaming economics and Disney’s CEO transition, with Josh D’Amaro set to take over at the March 18 meeting. Disney reported quarterly revenue of $25.98 billion and adjusted EPS of $1.63, while segment operating income fell 9% to $4.6 billion.
Novo Nordisk stock: Class B shares face Monday test after FDA squeeze forces Hims to pull $49 Wegovy copycat

Novo Nordisk stock: Class B shares face Monday test after FDA squeeze forces Hims to pull $49 Wegovy copycat

7 February 2026
Novo Nordisk Class B shares closed up 5.3% at 295.50 Danish crowns in Copenhagen after Hims & Hers said it would stop offering a compounded pill version of Wegovy following U.S. regulatory warnings. The move came after Novo called the Hims product “illegal mass compounding” and threatened legal action. Shares had fallen nearly 8% Thursday after Hims launched the pill. Trading resumes Monday.
Go toTop